RBD-specific polyclonal F(ab´)₂ fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.

4.4 Subgroup analysis Prespecified subgroup analysis according to baseline clinical status showed that no difference in primary outcome was noted in patients with moderate disease between groups (71 of 74 patients in INM005 group and 71 of 74 patients in placebo group) while an effect was noted in patients with severe disease (35 of 44 patients in the INM005 group and 33 of 50 patients in the placebo group) that did not reach statistical significance (odds ratio [95% CI]: 0•846 [0•45 to 1•58]; Fig.

also in 111,027 other papers